Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients [Yahoo! Finance]
Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) (FMS)
Last fresenius medical care ag american depositary shares (each representing 1/2 of an ordinary share) earnings: 7/31 04:03 pm
Check Earnings Report
US:NYSE Investor Relations:
freseniusmedicalcare.com/en/investors/investors-overview
Company Research
Source: Yahoo! Finance
Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) developed by Akebia. "We congratulate our partner Akebia on the FDA approval, which represents an important moment in our shared efforts toward improving the lives of dialysis patients with anemia due to CKD in the U.S.," said Hervé Gisserot, General Manager of CSL Vifor. "As we continue to deliver on our promise for patients and public health, we are eager to closely collaborate with our partners to make this new oral treatment option available to patients." "Patients receiving maintenance dialysis would benefit from additional therapeutic options that can effectively increase and maintain hemoglobin concentrations within guideline-recommended target ranges," said Glenn M. Chertow , M.D., M.P.
Show less
Read more
Impact Snapshot
Event Time:
FMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FMS alerts
High impacting Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) news events
Weekly update
A roundup of the hottest topics
FMS
News
- Fresenius Medical Care AG (NYSE: FMS) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.MarketBeat
- Fresenius Medical Care (ETR:FME) earnings and shareholder returns have been trending downwards for the last five years, but the stock soars 14% this past week [Yahoo! Finance]Yahoo! Finance
- Fresenius Medical Care AG (NYSE: FMS) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
- Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S. [Yahoo! Finance]Yahoo! Finance
- Dialysis Machines Market Analysis Forecast to 2033 - Technological Innovations and Global Market Trends [Yahoo! Finance]Yahoo! Finance
FMS
Earnings
- 8/3/23 - In-Line
FMS
Sec Filings
- 3/28/24 - Form 6-K
- 3/13/24 - Form 6-K
- 3/5/24 - Form 6-K
- FMS's page on the SEC website